N-methyl-4-propan-2-ylpiperidin-1-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-methyl-4-propan-2-ylpiperidin-1-amine
• 化学式: C₉H₂₀N₂
• 分子量: 156.27
• InChiKey: JFIQMXJUKYWDAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY
  申请人：Shenzhen TargetRx, Inc.

  公开号：EP3715343A1

  公开（公告）日：2020-09-30

  Disclosed are a diphenylaminopyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotopic derivatives thereof, a pharmaceutical composition comprising these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and may be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.

  本发明公开了一种对蛋白酪氨酸激酶具有抑制作用的二苯基氨基嘧啶化合物、其药学上可接受的盐、晶体形式、原药、代谢物、水合物、溶解物、立体异构体或同位素衍生物、包含这些化合物的药物组合物以及这些化合物的制备和使用方法。该化合物具有式（I）所代表的结构，可用于治疗ALK介导的癌症相关症状，如非小细胞肺癌、乳腺癌、神经肿瘤、食道癌、软组织癌、淋巴瘤或白血病。
• Dianilinopyrimidine compound for inhibiting kinase activity
  申请人：Shenzhen Targetrx, Inc.

  公开号：US11254696B2

  公开（公告）日：2022-02-22

  Disclosed are a dianilino pyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotopic derivatives thereof, a pharmaceutical composition containing these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and may be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.

  本发明公开了一种对蛋白酪氨酸激酶具有抑制作用的二苯胺基嘧啶化合物、其药学上可接受的盐、晶体形式、原药、代谢物、水合物、溶解物、立体异构体或同位素衍生物、含有这些化合物的药物组合物以及这些化合物的制备和使用方法。该化合物具有式（I）所代表的结构，可用于治疗ALK介导的癌症相关症状，如非小细胞肺癌、乳腺癌、神经肿瘤、食道癌、软组织癌、淋巴瘤或白血病。
• DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY
  申请人：Shenzhen TargetRx, Inc.

  公开号：US20210087213A1

  公开（公告）日：2021-03-25

  Disclosed are a dianilinopyrimidine compound having an inhibitory effect on protein tyrosine kinase, pharmaceutically acceptable salts, crystal forms, prodrugs, metabolites, hydrates, solvates, stereoisomers or isotopic derivatives thereof, a pharmaceutical composition containing these compounds, as well as preparation and use of these compounds. The compound has a structure as represented by formula (I), and may be used for treating ALK-mediated cancer-related symptoms, such as non-small cell lung cancer, breast cancer, nerve tumors, esophagus cancer, soft tissue cancer, lymphoma, or leukemia.